Transformative Urologic Care in a Pioneering Health System
The Fox Chase–Temple Urologic Institute represents an innovative partnership that unites the expertise of distinguished institutions within one health system in the pursuit of groundbreaking oncologic and benign urology care.
Our multidisciplinary teams, composed of internationally recognized urologic leaders, address the most challenging genitourinary malignancies as well as complex benign urologic conditions. By employing state-of-the-art robotic, minimally invasive, and open surgical techniques, our specialists provide comprehensive oncologic, reconstructive, and prosthetic care.
Moreover, our cutting-edge translational research programs offer patients access to some of the world's most promising clinical trials. This unique fusion of advanced clinical discovery, innovative treatment delivery, and transformative care ensures that our patients receive the highest caliber of urologic care available today.
View a complete list of presentations and posters by our faculty.
Visit AUA to browse the complete program.
Optimizing Treatment Strategies for Localized and Advanced Prostate Cancer
View this symposium presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education. Learn the most current strategies for optimally managing localized and advanced prostate cancer from the Fox Chase ...
Pioneering Surgical Techniques with Advanced Robotic Surgery
Temple robotic surgeons are making it possible for more patients to receive lifesaving therapies after being told they were out of options.
The New Department of Urology at Fox Chase Cancer Center
Built on strength: world-class specialists, innovative researchers, and clinical leaders.
FOX CHASE-TEMPLE UROLOGIC INSTITUTE - The Next Generation of Urology Care
Where groundbreaking oncologic and benign care unite within one health system
Urinary Incontinence in Women: Evaluation and Management
Dr. Joshua Cohn discusses urinary incontinence in women, focusing on the etiology, prevalence and diagnostic evaluation. He also discusses the various treatment options that may be most helpful for each patient.
FOX CHASE-TEMPLE UROLOGIC INSTITUTE - Physician Roster
New Fox Chase Clinical Trial Could Help Men With Intermediate-Risk Prostate Cancer Avoid Radical Treatment
Could NanoKnife be the future of prostate cancer care?
Aquablation: Changing the Surgical Landscape of BPH
Join Steve Sterious, MD FACS from the Fox Chase Cancer Center at Temple Health to discuss Aquablation and the changing surgical landscape of BPH.
Fox Chase Cancer Center Researchers Present Further Data on Potential Bladder-Sparing Treatment
Bladder removal is life-altering. This study examines when and why some patients may not need it.
Michael J. Metro, MD discusses the importance of proper diagnosis for urethral stricutres.
Transforming Cancer Care and Delivery
The new President and CEO of Fox Chase Cancer Center
Non-Onocologic Reconstructive Urologic Surgery
With a team that features national leaders in the field, Temple’s Robotic Urologic Surgery program is the gold standard in reconstructive surgery for patients who have experienced traumatic injury to the urinary tract, scarring from cancer ...
Comprehensive Cancer Care Demands Exceptional Teamwork, Collaboration and Leaders to Bring It to Life.
Centralizing scientific discovery, advanced research, and clinical care—all for a new therapeutic pathway.
Peyronie’s Disease Presentation and Assessment
Michael J. Metro, MD discusses history, presentation and assessment of Peyronie’s Disease.
A Salvage Treatment Jennifer Was Inspired to Salvage.
A Life-Saving Idea for Bladder Cancer Patients.
What is the Same and What Has Changed with the Artificial Urinary Sphincter?
The artificial urinary sphincter is an implantable device designed to treat incontinence in prostate cancer survivors. The device has existed for 50 years, and in that time, best practices around its use have undergone several paradigm shifts.
How to Perform Device-Free, Free-Handed Transperineal Prostate Biopsy
Fox Chase Cancer Center’s urologic oncology group shares an educational video that provides instruction on how to perform a device-free, free-handed transperineal prostate biopsy.
Cancer Is a Moving Target.
CBCT-Based Adaptive Radiation Therapy Tracks It Every Day of Treatment.
Adaptive radiation therapy allows clinicians to make daily adjustments in a patient’s treatment in real time while the patient is on the treatment table based on the cancer’s response to the radiation, position of the tumor, and the location ...
Dr. Laura Bukavina on the Front Lines of Research and War
Fighting for life everywhere she goes.
Fox Chase Urology Just Took a Big Leap Forward
A new benign urology team adds gravitas to a renowned cancer department.
Fox Chase Researchers Examine Racial Differences in Treatment and Outcomes of First-Line Therapies for Kidney Cancer
Digging into the "why" of racial disparity in kidney cancer outcomes.
Christine Amoroso Coordinates Treatment-Optimizing, Dedicated Intravesical Clinic
Amoroso is part of the nurse-led dedicated intravesical clinic that helps optimize treatment for patients and workflow for other physicians and nurses.
New Prognostic Model More Accurately Predicts Kidney Cancer Recurrence and Survival
Researchers at Fox Chase Cancer Center have developed a model that predicts disease recurrence and survival in patients with intermediate- and high-risk localized kidney cancer more accurately than existing prognostic models.
Kutikov Leads International Effort to Optimize Management of Adrenal Masses
Fox Chase’s Alexander Kutikov, MD, FACS, is leading an international effort to create a centralized, streamlined, point-of-care resource for the management of adrenal masses.